Thrivent Financial for Lutherans Buys 714 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Thrivent Financial for Lutherans raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 8.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,998 shares of the company’s stock after acquiring an additional 714 shares during the quarter. Thrivent Financial for Lutherans’ holdings in IDEXX Laboratories were worth $3,671,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Carolinas Wealth Consulting LLC bought a new stake in IDEXX Laboratories during the 1st quarter valued at $39,000. Atlas Capital Advisors LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at $44,000. General Partner Inc. bought a new stake in IDEXX Laboratories during the 4th quarter valued at $53,000. Lindbrook Capital LLC boosted its position in IDEXX Laboratories by 136.8% during the 4th quarter. Lindbrook Capital LLC now owns 135 shares of the company’s stock valued at $55,000 after acquiring an additional 78 shares in the last quarter. Finally, Intelligent Financial Strategies boosted its position in IDEXX Laboratories by 50.0% during the 4th quarter. Intelligent Financial Strategies now owns 150 shares of the company’s stock valued at $61,000 after acquiring an additional 50 shares in the last quarter. Institutional investors own 87.90% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $487.47 on Monday. The stock has a 50-day moving average of $481.46 and a two-hundred day moving average of $455.81. IDEXX Laboratories, Inc. has a one year low of $317.06 and a one year high of $515.79. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.71 and a current ratio of 1.08. The stock has a market cap of $40.41 billion, a P/E ratio of 58.66, a P/E/G ratio of 2.94 and a beta of 1.19.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, SVP Kathy V. Turner sold 2,000 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the completion of the transaction, the senior vice president now owns 7,380 shares in the company, valued at approximately $3,723,874.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 2,187 shares of IDEXX Laboratories stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $469.02, for a total transaction of $1,025,746.74. Following the completion of the transaction, the director now owns 872 shares in the company, valued at approximately $408,985.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Kathy V. Turner sold 2,000 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 14th. The shares were sold at an average price of $504.59, for a total value of $1,009,180.00. Following the transaction, the senior vice president now owns 7,380 shares of the company’s stock, valued at approximately $3,723,874.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,187 shares of company stock worth $2,518,927. Insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent analyst reports. The Goldman Sachs Group raised their price objective on IDEXX Laboratories from $465.00 to $530.00 and gave the stock a “buy” rating in a research report on Wednesday, January 25th. JPMorgan Chase & Co. raised their price objective on IDEXX Laboratories from $525.00 to $550.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 7th. Atlantic Securities raised their price objective on IDEXX Laboratories from $470.00 to $600.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 7th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, April 1st. Finally, Barclays lifted their price target on IDEXX Laboratories from $582.00 to $590.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 8th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $527.86.

IDEXX Laboratories Profile

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other.